Markus Proels
Dr Falk Pharma (Germany) · 23 works · 1,264 citations · h-index 10
Top works
- Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis
- norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
- Budesonide in previously untreated autoimmune hepatitis
- Budesonide versus Prednisone with Azathioprine for the Treatment of Autoimmune Hepatitis in Children and Adolescents
- A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA
- Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohnʼs disease: A randomized placebo-controlled trial
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- 989 BUDESONIDE 3MG TID IS SUPERIOR TO PREDNISONE IN COMBINATION WITH AZATHIOPRINE IN THE TREATMENT OF AUTOIMMUNE HEPATITIS
- Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study
- LBO-001 Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial
- Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid
- 29 BUDESONIDE 3 MG TID IN THE TREATMENT OF AUTOIMMUNE HEPATITIS (AIH) IN ADOLESCENTS, A SUBGROUP ANALYSIS OF THE EUROPEAN AIH-BUC-STUDY
- norUrsodeoxycholic acid (norUDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response
- Norucholic acid for the treatment of primary sclerosing cholangitis: baseline data from a phase III trial
- Glucuronidation directs systemically available norursodeoxcholic acid (norUDCA) to the kidney
- THU-103 Results froma phase 2a trial with the CD80 antagonist RhuDex as a second line treatment for primary biliary cholangitis
- S1153 An Induction Dose of 12 Mg/D Budesonide Improves Clinical Efficacy in Comparison to a Standard Continuous Dose of 9 mg/d Active Pediatric Crohn's Disease
- OS-115 Results from a phase 2a randomized trial with the transglutaminase 2 inhibitor ZED1227 in patients with MASLD
- Norucholsäure zur Behandlung der primären sklerosierenden Cholangitis: 96-Wochen-Ergebnisse der Phase 3 Studie NUC-5
- OS-007 Norucholic acid leads to biochemical and histologic improvement in primary sclerosing cholangitis: impact of concomitant ursodeoxycholic acid therapy